Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Amazighon Oct 04, 2021 1:42am
127 Views
Post# 33959643

RE:Sedar Oct 1

RE:Sedar Oct 1
HighSkies2019 wrote: Can someone chk on sedar and see what pdf file on Friday Oct 1 late in the evening .... I can't get it open ...just not sure if its one we already read....thx


We already read this one. It's the one about the law firm: Claritas Announces Shares for Services Agreement & Proposed Share Issuance SAN FRANCISCO, CA -- (September 30, 2021) Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the "Company" or "Claritas") is pleased to announce it has submitted the Companys services agreement containing shares for services agreements with its legal counsel Nox Law Corporation to the TSXV for its approval and wishes to issue shares for payment of services provided to the Company. The Company and its US subsidiary Kalytera Therapeutics (Delaware), Inc. entered into legal services agreements with Nox effective since April 2020 and July 2020, respectively, under which the Company and its subsidiary received and continue to receive US and Canadian legal services from Nox at hourly rates comparable to other corporate/securities boutique law firms minus a discount. Such other comparable industry hourly rates range from $300 to $500. Similar to other agreements for legal services, there are no specific terms for these agreements, however, either party can terminate the agreements by providing notice to the other. Under these agreements, payment of accounts due to Nox for services rendered can be paid in cash or securities of the Company as decided between the parties from time to time. Claritas wishes to be able to pay Nox in the securities of the Company and had submitted the mentioned services agreements and supporting documents to the TSXV for its review and approval in June, July and August 2021. Company and Nox intend to have US$17,944.68 plus any accrued interest be paid by the issuance of shares and warrants to Nox and have submitted their agreement with respect of the same to the TSXV. Should the TSXV approve the agreements this will enable the Company to pay Nox in shares and other securities of the Company from time to time, including for the proposed payment in shares and warrants described below, in accordance with TSXV policies. The Company will provide additional updates after TSXV approval of the relevant agreements and with respect of the issuance of any securities. Each issuance of securities to Nox by the Company for the payment of its accounts for services rendered will be subject to TSXV approval. The Company proposes to pay US$17,944.68 plus any accrued interest at the date of payment in common shares and 100,000 common share purchase warrants of the Company to Nox to pay for certain previous services rendered from July 2020 onward and for fees previously deferred for prior services. The amount payable includes taxes. The Company proposes to effect the issuances on the date of the TSXVs approval for the proposed issuances. The warrants will have a term of 2 years and an exercise price per share that is 10% premium to the prior trading days closing market price of the Companys common shares before the date of TSXVs approval of the issuance. The number of common shares to be issued to Nox shall be calculated by: Dividing US$17,944.68 plus any accrued interest as of the date of payment by the closing price of the common shares (as adjusted into US dollars for the exchange rate on the day of issuance) on the trading day prior to the TSXVs approval of the issuance minus a discount of 10%. By reference to the last closing price of the common shares on the TSXV on closing date of September 30, 2021 being CAD$0.285/share , the deemed price set for the issuance, should the issuance be approved by the exchange, is 10% discounted closing price of CAD$0.2565/share.
<< Previous
Bullboard Posts
Next >>